410 related articles for article (PubMed ID: 30638898)
21. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
23. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R; Pozza LD; Khaw SL; Fraser C; Revesz T; Chamberlain J; Mitchell R; Trahair TN; Bateman CM; Venn NC; Law T; Ong E; Heatley SL; McClure BJ; Meyer C; Marschalek R; Henderson MJ; Cross S; White DL; Kotecha RS
Pediatr Blood Cancer; 2021 May; 68(5):e28922. PubMed ID: 33638292
[TBL] [Abstract][Full Text] [Related]
24. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Dombret H; Stein A; Bonifacio M; Graux C; Faul C; Brüggemann M; Taylor K; Mergen N; Reichle A; Horst HA; Havelange V; Topp MS; Bargou RC
Leuk Lymphoma; 2020 Nov; 61(11):2665-2673. PubMed ID: 32619115
[TBL] [Abstract][Full Text] [Related]
25. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
26. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
[TBL] [Abstract][Full Text] [Related]
27. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
28. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
29. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
Handgretinger R; Zugmaier G; Henze G; Kreyenberg H; Lang P; von Stackelberg A
Leukemia; 2011 Jan; 25(1):181-4. PubMed ID: 20944674
[No Abstract] [Full Text] [Related]
30. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
Alcharakh M; Yun S; Dong Y; Vincelette ND; Daud M; Manzoor S; Riaz IB; Anwer F
Immunotherapy; 2016 Jul; 8(8):847-52. PubMed ID: 27381683
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
32. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
Zhou H; Wu X; Yang Z; Lu S; Zhang X; Yang X; Chen S; Wu D; Miao M
Invest New Drugs; 2024 Jun; 42(3):299-308. PubMed ID: 38662275
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
34. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
36. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
[TBL] [Abstract][Full Text] [Related]
38. Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
Mikhailova E; Popov A; Roumiantseva J; Budanov O; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khachatryan L; Pshonkin A; Ponomareva N; Boichenko E; Varfolomeeva S; Dinikina J; Novichkova G; Henze G; Karachunskiy A
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844406
[TBL] [Abstract][Full Text] [Related]
39. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.
Yu J; Wang W; Huang H
Hematology; 2019 Dec; 24(1):199-207. PubMed ID: 30479190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]